Andrew Tsai
analystMale0.0Global Dominance: 0.00%
Andrew Tsai is a financial analyst at Jefferies, specializing in the biotechnology sector. He is noted for his optimistic outlook on the potential success of azetukalner, predicting that it could become a leading epilepsy treatment and generate over a billion dollars in annual sales.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Jefferies analyst Andrew Tsai said in a recent note that the drug has already produced one of the most compelling pivotal datasets in focal epilepsy.
Xenon awaiting critical epilepsy drug study results that could lead to FDA approvalThe Globe and Mail·
Canada· 2026-03-02
Canada· 2026-03-02
